Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer

Abstract Podocalyxin overexpression associates with poor survival in pancreatic cancer (PDAC). We investigated whether podocalyxin expression correlates with treatment response or survival in neoadjuvant-treated PDAC. Through immunohistochemistry, we evaluated podocalyxin expression in 88 neoadjuvan...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Annika Eurola, Ari Ristimäki, Harri Mustonen, Anna-Maria Nurmi, Jaana Hagström, Caj Haglund, Hanna Seppänen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6018413b766b4e3fbc35e9082e2e82a3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6018413b766b4e3fbc35e9082e2e82a3
record_format	dspace
spelling	oai:doaj.org-article:6018413b766b4e3fbc35e9082e2e82a32021-12-02T16:51:03ZImpact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer10.1038/s41598-021-89134-22045-2322https://doaj.org/article/6018413b766b4e3fbc35e9082e2e82a32021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89134-2https://doaj.org/toc/2045-2322Abstract Podocalyxin overexpression associates with poor survival in pancreatic cancer (PDAC). We investigated whether podocalyxin expression correlates with treatment response or survival in neoadjuvant-treated PDAC. Through immunohistochemistry, we evaluated podocalyxin expression in 88 neoadjuvant and 143 upfront surgery patients using two antibodies. We developed a six-tier grading scheme for neoadjuvant responses evaluating the remaining tumor cells in surgical specimens. Strong podocalyxin immunopositivity associated with poor survival in the patients responding poorly to the neoadjuvant treatment (HR 4.16, 95% CI 1.56–11.01, p = 0.004), although neoadjuvant patients exhibited generally low podocalyxin expression (p = 0.017). Strong podocalyxin expression associated with perineural invasion (p = 0.003) and lack of radiation (p = 0.036). Two patients exhibited a complete neoadjuvant response, while a strong neoadjuvant response (≤ 5% of residual tumor cells) significantly associated with lower stage, pT-class and grade, less spread to the regional lymph nodes, less perineural invasion, and podocalyxin negativity (p < 0.05, respectively). A strong response predicted better survival (HR 0.28, 95% CI 0.09–0.94, p = 0.039). In conclusion, strong podocalyxin expression associates with poor survival among poorly responding neoadjuvant patients. A good response associates with podocalyxin negativity. A strong response associates with better outcome.Annika EurolaAri RistimäkiHarri MustonenAnna-Maria NurmiJaana HagströmCaj HaglundHanna SeppänenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Annika Eurola Ari Ristimäki Harri Mustonen Anna-Maria Nurmi Jaana Hagström Caj Haglund Hanna Seppänen Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer
description	Abstract Podocalyxin overexpression associates with poor survival in pancreatic cancer (PDAC). We investigated whether podocalyxin expression correlates with treatment response or survival in neoadjuvant-treated PDAC. Through immunohistochemistry, we evaluated podocalyxin expression in 88 neoadjuvant and 143 upfront surgery patients using two antibodies. We developed a six-tier grading scheme for neoadjuvant responses evaluating the remaining tumor cells in surgical specimens. Strong podocalyxin immunopositivity associated with poor survival in the patients responding poorly to the neoadjuvant treatment (HR 4.16, 95% CI 1.56–11.01, p = 0.004), although neoadjuvant patients exhibited generally low podocalyxin expression (p = 0.017). Strong podocalyxin expression associated with perineural invasion (p = 0.003) and lack of radiation (p = 0.036). Two patients exhibited a complete neoadjuvant response, while a strong neoadjuvant response (≤ 5% of residual tumor cells) significantly associated with lower stage, pT-class and grade, less spread to the regional lymph nodes, less perineural invasion, and podocalyxin negativity (p < 0.05, respectively). A strong response predicted better survival (HR 0.28, 95% CI 0.09–0.94, p = 0.039). In conclusion, strong podocalyxin expression associates with poor survival among poorly responding neoadjuvant patients. A good response associates with podocalyxin negativity. A strong response associates with better outcome.
format	article
author	Annika Eurola Ari Ristimäki Harri Mustonen Anna-Maria Nurmi Jaana Hagström Caj Haglund Hanna Seppänen
author_facet	Annika Eurola Ari Ristimäki Harri Mustonen Anna-Maria Nurmi Jaana Hagström Caj Haglund Hanna Seppänen
author_sort	Annika Eurola
title	Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer
title_short	Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer
title_full	Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer
title_fullStr	Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer
title_full_unstemmed	Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer
title_sort	impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6018413b766b4e3fbc35e9082e2e82a3
work_keys_str_mv	AT annikaeurola impactofhistologicalresponseafterneoadjuvanttherapyonpodocalyxinasaprognosticmarkerinpancreaticcancer AT ariristimaki impactofhistologicalresponseafterneoadjuvanttherapyonpodocalyxinasaprognosticmarkerinpancreaticcancer AT harrimustonen impactofhistologicalresponseafterneoadjuvanttherapyonpodocalyxinasaprognosticmarkerinpancreaticcancer AT annamarianurmi impactofhistologicalresponseafterneoadjuvanttherapyonpodocalyxinasaprognosticmarkerinpancreaticcancer AT jaanahagstrom impactofhistologicalresponseafterneoadjuvanttherapyonpodocalyxinasaprognosticmarkerinpancreaticcancer AT cajhaglund impactofhistologicalresponseafterneoadjuvanttherapyonpodocalyxinasaprognosticmarkerinpancreaticcancer AT hannaseppanen impactofhistologicalresponseafterneoadjuvanttherapyonpodocalyxinasaprognosticmarkerinpancreaticcancer
_version_	1718382980239458304

Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer

Ejemplares similares